Sasanlimab in Combination with BCG Improves EFS in Patients with BCG-Naïve, High-Risk NMIBC January 15, 2025
Adjuvant Libtayo® (cemiplimab) Significantly Improves DFS After Surgery in High-Risk CSCC in Ph 3 Trial January 15, 2025
Positive Update provided on Ph 2a Arm of IMM-1-104 in Combination with Modified FOLFIRINOX for 1L Pancreatic Cancer January 15, 2025
RYBREVANT® (amivantamab-vmjw) + LAZCLUZE™ (lazertinib) shows statistically significant and clinically meaningful improvement in OS versus osimertinib January 15, 2025
New Sarclisa SC formulation met co-primary endpoints in the IRAKLIA Ph 3 study in multiple myeloma January 15, 2025
Positive Initial Clinical Data from Ph 1 Clinical Trial of Emiltatug Ledadotin (XMT-1660) Announced; Expansion in TNBC Initiated January 15, 2025
Interim Data Demonstrating Safety & Confirmed Clinical Responses of ADG126 up to 10 mg/kg with Repeat Cycles in Combination with Anti-PD-1 Therapy from Dose Escalation Portion of Ph 1b/2 Trial Announced January 11, 2025
Positive Topline Results from China GC/GEJ Ph 2 Trial of Claudin18.2 CAR-T (Satri-cel) announced December 31, 2024
Positive Interim Ph 2 Data of Elraglusib in First Line Treatment of Metastatic Pancreatic Cancer Announced December 26, 2024
FAILED TRIAL: Ph 3 Bridging Trial in China in Patients with R/R AML did not demonstrate favorable benefit for uproleselan December 26, 2024
Initial clinical results from ongoing KYANITE-1 study of inhaled KB707 in patients with solid tumors of the lung announced December 25, 2024
Safety Review Committee Approval of Opening 3rd Cohort and Preliminary Results from 1st Cohort in Ph 1 TTX-MC138 Trial Announced December 25, 2024
FAILED TRIAL: FIRST trial of Jemperli (dostarlimab) + chemo and Zejula maintenance +/- avastin met primary endpoint of PFS but not OS in 1L advanced ovarian cancer December 25, 2024
CAN-2409 Achieved Primary Endpoint in Ph 3 Prostate Cancer Trial, Showing Significantly Improved DFS December 18, 2024
Positive Initial Data from LOTIS-7 Trial of ZYNLONTA® in Combination with Bispecific Antibody in Patients with R/R LBCL Announced December 18, 2024
Data Characterizing Mutated KRAS Genotype and Clinical Outcomes in Patients with Advanced NSCLC Treated with Mecbotamab Vedotin (Mec-V) presented December 18, 2024
Continued Strong Improvement in OS Data from Ph 2 OVATION 2 Study of IMNN-001 Announced December 18, 2024
Positive Initial Data from First-line RAS-mutated mCRC Ph 2 CRDF-004 trial evaluating onvansertib + SoC Announced December 18, 2024
Data shows strong OS, PFS, and durability from combination of efti + pembrolizumab in difficult-to-treat head and neck cancer patients with PD-L1 CPS <1 December 18, 2024
Positive Results of the Lunresertib and Camonsertib Combination from the MYTHIC Ph 1 Gynecologic Expansion Clinical Trial Announced December 18, 2024
Cretostimogene Grenadenorepvec Monotherapy Data Demonstrates Sustained, Durable Complete Responses in High-Risk BCG-Unresponsive NMIBC December 10, 2024
Ph 3 POD1UM-304 trial of Retifanlimab (Zynyz®) + Chemo met primary endpoint of OS and all secondary endpoints in patients with 1L metastatic NSCLC December 10, 2024
Petosemtamab Monotherapy Interim Data Continues to Demonstrate Clinically Meaningful Activity in 2L+ r/m HNSCC December 10, 2024
